


Claims

1. Indazole compounds of formula 1,



Formula 1

Wherein:

R¹ are hydrogen or alkyl or aryl or heteroaryl;

R² are H or halogen

R³, R⁴, R⁵, and R⁶ are independently hydrogen or alkyl, aryl, hetero aryl;

any two adjacent groups selected from R³, R⁴, R⁵, and R⁶ may form a 3-8 membered cycle which may additionally contain hetero atoms; and their stereoisomers and pharmaceutically acceptable salt thereof.

2. Indazole compounds of formula 1 as claimed in claim 1 are represented by the following compounds
- 5-Chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indazole;
 - 5-Chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-3a,7a-dihydro-1H-indazole;
 - 5-chloro-3-(3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazol-2-yl)-1H-indazole ;
 - 5-Chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-1-ethyl-1H-indazole;
 - 1-Benzyl-5-chloro-3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indazole;
 - 3-(4,5-dihydro-1H-imidazol-2-yl)-1H-indazole;
 - 3-(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indazole;
 - 3-(3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazol-2-yl)-1H-indazole.
3. A process for the preparation of Indazole compounds of formula 1 as claimed in claim 1, wherein the said process comprises the steps of;
- i. converting 5-Chloro isatin (1) into 5-chloro indazole 3-carboxylic acid (2);
 - ii. treating the compound 5-chloro indazole 3-carboxylic acid (2) with isobutyl chloroformate and N-methylmorpholine under argon followed by reaction with aq. ammonia to obtain 5-chloro-1H-indazole-3-carboxamide (3);
 - iii. treating the compound 5-chloro-1H-indazole-3-carboxamide (3) with pyridine and trifluoroacetic anhydride to obtain cyano compound (4);
 - iv. reacting cyano compound (4) with potassium carbonate and alkyl halide in a solvent selected from acetone to obtain substituted indazole carbonitrile;
 - v. reacting substituted indazole carbonitrile with diamine in presence of P₂S₅ to obtain compounds of general formula 1
4. A process as claimed in claim 3, wherein alkyl halide used in step (iv) is selected from the group consisting of ethyl bromide, methyl iodide, benzyl bromide.
5. A process as claimed in claim 3, wherein diamine used in step (v) is selected from the group consisting of 1,2-Cyclohexanediamine, ethylene diamine.
6. A pharmaceutical formulation comprising compound of Formula 1 as claimed in claim 1 as an active ingredient, or their stereoisomers, and pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients.
7. Indazole compounds of formula 1 as claimed in claim 1, wherein said compounds are for administration to a mammal in a therapeutically effective amount of a compound of Formula 1, or their stereoisomers, and pharmaceutically acceptable salt thereof.